Seventure et al. sell Endocontrol to trade
A consortium of VCs have sold their stakes in France-based surgical robotics developer Endocontrol to US-based life sciences company Canady Life Sciences.
Clement Vidal, Endocontrol's CEO and co-founder, will remain the CEO of the business.
CM-CIC Capital Innovation and Sudinnova invested €1.05m in Endocontrol's series-A round in 2007. Seventure Partners then led a €3m series-B round for the company alongside Vizille and Sudinnova three years later.
Most recently, Seventure, CM-CIC and French consulting and engineering company Viveris Management injected €4m into Endocontrol in a series-C in 2013. The round was earmarked for research and development activities, for new equipment, and to fund international expansion, with a focus on Asia and the Middle East.
Company
Founded in 2006 and based in La Tronche, Endocontrol designs, manufactures and markets robotics-assisted services for mini-invasive and laparoscopic surgery.
The company manufactures motorised foot- and voice-controlled robotic endoscopic positioners for laparoscopy and ultra-compact motorised uterus positioners for gynecologic surgery. Endocontrol has also developed a 5mm motorised articulated surgery instrument that gives access to intra-abdominal areas and a robotic needle holder.
The company has sold more than 200 robots worldwide.
People
Endocontrol – Clement Vidal (CEO, co-founder).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









